News from shionogi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 20, 2017, 10:19 ET Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD)

Shionogi & Co., Ltd. (hereafter "Shionogi") announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of...

Sep 28, 2017, 11:02 ET Shionogi To Highlight Research On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188, A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At IDWeek 2017

Shionogi & Co., Ltd. (hereafter "Shionogi") today announced it will share the latest data on cefiderocol (S-649266), an investigational siderophore...

Sep 25, 2017, 09:02 ET Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that lusutrombopag (S-888711), an investigational, once-daily, orally administered, small...

Sep 13, 2017, 09:12 ET S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference

Results of a S-033188 Phase 3 study in influenza patients (CAPSTONE-1) were released at the 6th European Scientific Working Group on Influenza...

Aug 03, 2017, 08:00 ET Shionogi Inc. President and CEO John Keller to Receive Innovation Award from NY American Chemical Society CME Group

The Chemical Marketing and Economics (CME) group of the American Chemical Society's New York Section, and Shionogi Inc., announced that Dr. John...

Jul 24, 2017, 08:01 ET Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients

Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that S-033188, a novel cap-dependent endonuclease inhibitor targeting influenza,...

Jun 01, 2017, 08:01 ET Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe (ASM) Meeting

Shionogi & Co., Ltd. (hereafter "Shionogi") will present key results of several studies for cefiderocol (S-649266), a late-stage investigational...

Apr 22, 2017, 08:00 ET Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin

Shionogi & Co., Ltd. today announced it will present for the first time clinical trial efficacy results, as well as supportive in vitro data, on...

Mar 10, 2017, 09:15 ET Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena® From Shionogi Inc.

Duchesnay, a specialty pharma company with a long-standing commitment to women's health, has acquired exclusive U.S. and Canadian rights to market...

Jan 12, 2017, 07:01 ET Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial

Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development,...

Sep 07, 2016, 12:02 ET Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation

Shionogi today presented positive results of a 52-week, placebo-controlled, phase III study (COMPOSE III) of naldemedine in treating opioid-induced...

Jun 06, 2016, 08:13 ET SHIONOGI ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION IN THE U.S. FOR NALDEMEDINE FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION

Shionogi today announced that the New Drug Application (NDA) submitted in the U.S. for naldemedine, a once-daily, oral 0.2 mg tablet, has been...

May 23, 2016, 01:37 ET Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation

Shionogi today announced positive results from two identically-designed 12 week phase III studies (COMPOSE I and II) demonstrating consistent...

Mar 30, 2016, 07:14 ET Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

Shionogi today announced that the company submitted New Drug Applications (NDAs) in Japan and the U.S. for a once-daily, oral 0.2 mg tablet of...

Feb 19, 2016, 08:03 ET Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved...